LLOYD Laboratories Inc. on Thursday said they are waiting for the emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the production and distribution of the anti-Covid-19 drug, molnupiravir, in the country.
In a virtual briefing on Thursday, Lloyd business development director Christopher Bamba said they originally applied for a certificate of product registration (CPR) but changed it to an EUA.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.